Vineti: Keeping cell therapies on track

How Vineti's GMP-ready platform connects the cell therapy supply chain

Drawing on its experience with CAR T cell therapies, Vineti has developed a cloud-based software platform that standardizes processes and drives down costs in the supply chain for personalized medicines.

According to Vineti Inc. CEO Amy DuRoss, the company was incubated at GE Ventures after an undisclosed company approached the investor in 2014 about a CAR T cell therapy then in clinical trials.

“They realized it really presented them with the most complex supply chain of logistics workflow requirements in the history of

Read the full 821 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE